Chromosomal region tied to aggressive forms of PCa

New Orleans-Scientists from two Cleveland institutions have identifieda chromosomal region they believe contains a gene or genes associated withaggressive forms of prostate cancer. Tests for molecular markers of geneticabnormalities in this region could some day identify men with prostate cancerwho warrant aggressive therapies, as well as spare some men from treatment.

Related Videos

Related Content

Advertisement

January 20th 2025

ROBUST I: Optilume maintains durable efficacy, safety for urethral strictures

Hannah Clarke

Functional success was achieved in 58% of patients at 5-year follow-up.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

January 18th 2025

Leveraging the full potential of APPs: Mark Edney, MD, on tips for successful collaboration

Mark T. Edney, MD

"There are far more people presenting to us for care than we have people able to provide it. The APPs are going to be a critical part of trying to solve that puzzle," says Mark T. Edney, MD.

November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

January 17th 2025

Illuccix approved in Europe for detection of PSMA-positive lesions

Hannah Clarke

The European approval of Illuccix adds on to prior approvals in the US, Australia, and Canada.

January 17th 2025

Challenges in plasmacytoid urothelial carcinoma underscore need for novel treatment options

Fed Ghali, MD

“If patients are not experiencing a clear clinical benefit for chemotherapy prior to surgery, we need to be really thoughtful about how we use it,” says Fed Ghali, MD.

Related Content

Advertisement

January 20th 2025

ROBUST I: Optilume maintains durable efficacy, safety for urethral strictures

Hannah Clarke

Functional success was achieved in 58% of patients at 5-year follow-up.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

January 18th 2025

Leveraging the full potential of APPs: Mark Edney, MD, on tips for successful collaboration

Mark T. Edney, MD

"There are far more people presenting to us for care than we have people able to provide it. The APPs are going to be a critical part of trying to solve that puzzle," says Mark T. Edney, MD.

November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

January 17th 2025

Illuccix approved in Europe for detection of PSMA-positive lesions

Hannah Clarke

The European approval of Illuccix adds on to prior approvals in the US, Australia, and Canada.

January 17th 2025

Challenges in plasmacytoid urothelial carcinoma underscore need for novel treatment options

Fed Ghali, MD

“If patients are not experiencing a clear clinical benefit for chemotherapy prior to surgery, we need to be really thoughtful about how we use it,” says Fed Ghali, MD.